To cite this paper use one of the standards below:
Parkinson's disease (PD) involves α-synuclein oligomer (αSynO) toxicity, yet the receptors mediating this remain elusive. This study investigated Cellular Prion Protein (PrPc) as a mediator of αSynO-induced neurodegeneration. All procedures adhered to the guidelines set by the Animal Use Ethics Committee (CEUA) of the Health Sciences Center (CCS) of UFRJ, approved by protocol number A6/19-001-16. Human transcriptomic analysis showed PRNP upregulation in idiopathic PD, correlating with regional vulnerability, with networks linked to membrane rafts and synaptic vesicles. Single-cell RNA-seq showed PRNP is predominantly neuronal, with low microglial expression, suggesting a neuron-autonomous mechanism. Stereotaxic intrastriatal αSynO was injected into wild-type (WT), PrPc-knockout (PrnpKO), and PrPC-overexpressing (Tg20) mice. At 30 days, PrPc expression altered baseline motor behavior (rotarod and pole test). After αSynO injection, Tg20 mice showed the worst functional decline and greatest Tyrosine Hydroxylase loss in the ipsilateral caudate-putamen, while PrnpKO was protected. RT-qPCR showed selective cytokine exacerbation (TNF-α, IL-1β, IL-6) only in Tg20-αSO, whereas WT and PrnpKO showed reduced homeostatic markers (Arg-1, MMP-9). Given microglia's role as primary cytokine-secreting cells in PD, Iba1+ morphology was quantified in caudate-putamen. Tg20 microglia showed the most reactive baseline morphology (largest perimeter, area, branching, junctions, arborization, intersections). αSynO increased these parameters across all groups, but Tg20-αSynO remained the most reactive, mirroring its selective cytokine upregulation. Given low microglial PRNP expression, findings suggest PrPc-driven neuronal stress secondarily recruits a deleterious microglial response. Overall, PrPc levels determines nigrostriatal vulnerability to αSynO, positioning the PrPc-αSynO interaction as a neuron-autonomous therapeutic target with downstream effects on microglial activation.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper